IASO Bio Presented the Outcomes of Relapsed/Refractory Multiple Myeloma (R/RMM) Patients with Renal Impairment Treated with Equecabtagene Autoleucel (Fucaso™) at 2024 IMS Annual Meeting ...Middle East

SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 27, 2024 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, today announced a poster...

Hence then, the article about iaso bio presented the outcomes of relapsed refractory multiple myeloma r rmm patients with renal impairment treated with equecabtagene autoleucel fucaso at 2024 ims annual meeting was published today ( Friday 27/09/2024 - 10:57 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( IASO Bio Presented the Outcomes of Relapsed/Refractory Multiple Myeloma (R/RMM) Patients with Renal Impairment Treated with Equecabtagene Autoleucel (Fucaso™) at 2024 IMS Annual Meeting )

Also on site :

• ABC Explains 'General 'Hospital' Preemption, Sets New Airdate
• Will Trent's Erika Christensen On The Significance Of Angie Having A Girl, Her Engagement To Seth, And What Changes (And Doesn't) With Will
• US trade with Southeast Asia and Taiwan surging despite Trump tariffs